Biologic Treatment Options for Retinal Neovascularization in Behçet's Disease. (2nd January 2019)

• Record Type: Journal Article
• Authors: Markomichelakis, Nikos N.; Aissopou, Evaggelia K.; Maselos, Stelios; Tugal-Tutkun, Ilknur; Sfikakis, Petros P.
• Is Part Of: Ocular immunology and inflammation. Volume 27:Number 1(2019)
• Page Start: 51
• Page End: 57
• Publication Date: 2019-01-02
• Subjects: Anti-TNF agents -- Behçet's disease -- infliximab -- interferon α-2a -- retinal neovascularization; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2017.1332228
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose : Relapsing ocular inflammation occurs in about 70% of patients with Behçet's disease (BD) and can lead to permanent loss of vision. Neovascularization of the optic disc (NVD) or elsewhere in the retina (NVE) is a relatively uncommon but severe complication that lacks standardized treatment. Methods : We report on the therapeutic use of anti-TNF monoclonal antibodies for BD-associated NVD and NVE in one pediatric patient (subcutaneous adalimumab) and one young man (intravenous infliximab). Also, we review the previously published experience on biologic therapeutic options, namely anti-TNF agents and interferon-alpha in a total of three and eight patients, respectively. Results : A fast-onset therapeutic effect was observed in both patients leading to complete regression of neovascularizations. Conclusions : Both options may lead to regression of neovascularization, thus preventing loss of vision, but comparative studies need to determine the optimal treatment for this sight-threatening complication of BD.